The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); GRAIL (I); Pfizer (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; bioTheranostics; Cyclacel; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; mersana; Novartis; Oncosec; pfizer; Puma Biotechnology; Seagen
Speakers' Bureau - Lilly
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer
Other Relationship - Genentech; Immunomedics
 
Melissa Kate Accordino
Honoraria - Incrowd; M3; Massive Bio; Sermo
Other Relationship - Onclive
 
Codruta Chiuzan
No Relationships to Disclose
 
Prabhjot Singh Mundi
No Relationships to Disclose
 
Meghna S. Trivedi
No Relationships to Disclose
 
Yelena Novik
No Relationships to Disclose
 
Amy Tiersten
Consulting or Advisory Role - AstraZeneca; Eisai; Immunomedics; Novartis; Puma Biotechnology; Roche/Genentech
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Novartis; pfizer
 
George Raptis
No Relationships to Disclose
 
Lea N. Baer
No Relationships to Disclose
 
Sun Young Oh
No Relationships to Disclose
 
Amelia Bruce Zelnak
No Relationships to Disclose
 
Kari Braun Wisinski
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; Eisai; Eisai; Genomic Health; Novartis Institutes for BioMedical Research; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Context Therapeutics (Inst); Genentech (Inst); Novartis (Inst); Oncoceutics (Inst); Pfizer; Pfizer; Sanofi (Inst)
 
Eleni Andreopoulou
No Relationships to Disclose
 
William John Gradishar
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Genentech/Roche; merck; Pfizer; Puma Biotechnology; Seagen
 
Erica Stringer-Reasor
No Relationships to Disclose
 
Sonya A. Reid
Honoraria - Novartis
Research Funding - Agendia
 
Anne O'Dea
Honoraria - Daiichi Sankyo/Astra Zeneca; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Novartis; Pfizer; Puma Biotechnology; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Pfizer; Puma Biotechnology
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Pfizer; Puma Biotechnology
 
Ruth O'Regan
Honoraria - AstraZeneca/MedImmune; bioTheranostics; Genentech; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; Puma Biotechnology; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; bioTheranostics; Genentech; ImmunogenX; Lilly; Macrogenics; Novartis; Puma Biotechnology; Seagen
Research Funding - Novartis (Inst); Puma Biotechnology (Inst)
 
Katherine D. Crew
No Relationships to Disclose
 
Dawn L. Hershman
Consulting or Advisory Role - AIM Specialty Health